Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents

Leandro J. Carreño, Noemí A. Saavedra-Ávila, Steven A. Porcelli

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Certain types of glycolipids have been found to have remarkable immunomodulatory properties as a result of their ability to activate specific T lymphocyte populations with an extremely wide range of immune effector properties. The most extensively studied glycolipid reactive T cells are known as invariant natural killer T (iNKT) cells. The antigen receptors of these cells specifically recognize certain glycolipids, most notably glycosphingolipids with α-anomeric monosaccharides, presented by the major histocompatibility complex class I-like molecule CD1d. Once activated, iNKT cells can secrete a very diverse array of pro- and anti-inflammatory cytokines to modulate innate and adaptive immune responses. Thus, glycolipid-mediated activation of iNKT cells has been explored for immunotherapy in a variety of disease states, including cancer and a range of infections. In this review, we discuss the design of synthetic glycolipid activators for iNKT cells, their impact on adaptive immune responses and their use to modulate iNKT cell responses to improve immunity against infections and cancer. Current challenges in translating results from preclinical animal studies to humans are also discussed.

Original languageEnglish (US)
Article numbere69
JournalClinical and Translational Immunology
Volume5
Issue number4
DOIs
StatePublished - Apr 1 2016

Fingerprint

Natural Killer T-Cells
Glycolipids
Adaptive Immunity
CD1d Antigen
T-Lymphocytes
Glycosphingolipids
Antigen Receptors
Monosaccharides
Infection
Major Histocompatibility Complex
Innate Immunity
Immunotherapy
Immunity
Neoplasms
Anti-Inflammatory Agents
Cytokines
Population

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents. / Carreño, Leandro J.; Saavedra-Ávila, Noemí A.; Porcelli, Steven A.

In: Clinical and Translational Immunology, Vol. 5, No. 4, e69, 01.04.2016.

Research output: Contribution to journalReview article

@article{af07e7f0c3bc46e1b5dfc6fe695073b7,
title = "Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents",
abstract = "Certain types of glycolipids have been found to have remarkable immunomodulatory properties as a result of their ability to activate specific T lymphocyte populations with an extremely wide range of immune effector properties. The most extensively studied glycolipid reactive T cells are known as invariant natural killer T (iNKT) cells. The antigen receptors of these cells specifically recognize certain glycolipids, most notably glycosphingolipids with α-anomeric monosaccharides, presented by the major histocompatibility complex class I-like molecule CD1d. Once activated, iNKT cells can secrete a very diverse array of pro- and anti-inflammatory cytokines to modulate innate and adaptive immune responses. Thus, glycolipid-mediated activation of iNKT cells has been explored for immunotherapy in a variety of disease states, including cancer and a range of infections. In this review, we discuss the design of synthetic glycolipid activators for iNKT cells, their impact on adaptive immune responses and their use to modulate iNKT cell responses to improve immunity against infections and cancer. Current challenges in translating results from preclinical animal studies to humans are also discussed.",
author = "Carre{\~n}o, {Leandro J.} and Saavedra-{\'A}vila, {Noem{\'i} A.} and Porcelli, {Steven A.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1038/cti.2016.14",
language = "English (US)",
volume = "5",
journal = "Clinical and Translational Immunology",
issn = "2050-0068",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents

AU - Carreño, Leandro J.

AU - Saavedra-Ávila, Noemí A.

AU - Porcelli, Steven A.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Certain types of glycolipids have been found to have remarkable immunomodulatory properties as a result of their ability to activate specific T lymphocyte populations with an extremely wide range of immune effector properties. The most extensively studied glycolipid reactive T cells are known as invariant natural killer T (iNKT) cells. The antigen receptors of these cells specifically recognize certain glycolipids, most notably glycosphingolipids with α-anomeric monosaccharides, presented by the major histocompatibility complex class I-like molecule CD1d. Once activated, iNKT cells can secrete a very diverse array of pro- and anti-inflammatory cytokines to modulate innate and adaptive immune responses. Thus, glycolipid-mediated activation of iNKT cells has been explored for immunotherapy in a variety of disease states, including cancer and a range of infections. In this review, we discuss the design of synthetic glycolipid activators for iNKT cells, their impact on adaptive immune responses and their use to modulate iNKT cell responses to improve immunity against infections and cancer. Current challenges in translating results from preclinical animal studies to humans are also discussed.

AB - Certain types of glycolipids have been found to have remarkable immunomodulatory properties as a result of their ability to activate specific T lymphocyte populations with an extremely wide range of immune effector properties. The most extensively studied glycolipid reactive T cells are known as invariant natural killer T (iNKT) cells. The antigen receptors of these cells specifically recognize certain glycolipids, most notably glycosphingolipids with α-anomeric monosaccharides, presented by the major histocompatibility complex class I-like molecule CD1d. Once activated, iNKT cells can secrete a very diverse array of pro- and anti-inflammatory cytokines to modulate innate and adaptive immune responses. Thus, glycolipid-mediated activation of iNKT cells has been explored for immunotherapy in a variety of disease states, including cancer and a range of infections. In this review, we discuss the design of synthetic glycolipid activators for iNKT cells, their impact on adaptive immune responses and their use to modulate iNKT cell responses to improve immunity against infections and cancer. Current challenges in translating results from preclinical animal studies to humans are also discussed.

UR - http://www.scopus.com/inward/record.url?scp=84992750197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992750197&partnerID=8YFLogxK

U2 - 10.1038/cti.2016.14

DO - 10.1038/cti.2016.14

M3 - Review article

VL - 5

JO - Clinical and Translational Immunology

JF - Clinical and Translational Immunology

SN - 2050-0068

IS - 4

M1 - e69

ER -